Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2020 16:05 ET | Source: MyoKardia, Inc.

Data from EXPLORER-HCM Study Selected for Virtual Late-Breaker Presentation at the European Society of Cardiology Congress 2020

BRISBANE, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the company will present 38-week data from its pivotal Phase 3 EXPLORER-HCM clinical trial...
August 05, 2020 16:05 ET | Source: MyoKardia, Inc.

MyoKardia to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

BRISBANE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that Jake Bauer, Chief Business Officer, will present at the 2020 Wedbush PacGrow Healthcare...
August 04, 2020 16:05 ET | Source: MyoKardia, Inc.

MyoKardia Reports Second Quarter 2020 Financial Results

BRISBANE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today reported financial results for the second quarter ended June 30, 2020. “The second quarter of 2020 was one...
August 03, 2020 09:52 ET | Source: MyoKardia, Inc.

CORRECTION: MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten

BRISBANE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Monday, August 3rd by MyoKardia, Inc. (Nasdaq: MYOK), please note that the second quote by Jeffrey...
August 03, 2020 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten

BRISBANE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) announced that the first patient has been dosed in the Phase 3 VALOR-HCM clinical trial. VALOR-HCM will enroll...
July 28, 2020 08:00 ET | Source: MyoKardia, Inc.

MyoKardia to Report Second Quarter 2020 Financial Results on Tuesday, August 4, 2020

BRISBANE, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will report second quarter financial and operating results on Tuesday, August 4, 2020....
July 23, 2020 16:05 ET | Source: MyoKardia, Inc.

MyoKardia Announces Receipt of Breakthrough Therapy Designation from FDA for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic Cardiomyopathy

BRISBANE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to...
July 21, 2020 07:30 ET | Source: MyoKardia, Inc.

MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies

BRISBANE, Calif. and CAMBRIDGE, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for...
July 06, 2020 08:00 ET | Source: MyoKardia, Inc.

MyoKardia Announces Appointment of Denelle J. Waynick as General Counsel and Corporate Secretary

BRISBANE, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary. Ms. Waynick joins...
June 22, 2020 08:00 ET | Source: MyoKardia, Inc.

MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC’s HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure

Danicamtiv was Well Tolerated; Demonstrated Improvements in Cardiac Contractility and Preserved Diastolic Function in Patients with Stable Heart Failure with Reduced Ejection Fraction New...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right